spacer
CDC Home > HIV/AIDSTopics > Statistics and Surveillance > Reports
Enhanced Perinatal Surveillance—Participating Areas in the United States and Dependent Areas, 2000–2003
spacer
HIV/AIDS Surveillance Supplemental Report - Volume 13, Number 4
spacer
Enhanced Perinatal Surveillance—Participating Areas in the United States and Dependent Areas, 2000–2003
space
arrow Cover
space
arrow Commentary
space
arrow Figure 1
space
arrow Table 1
space
arrow Table 2
space
space
arrow Table 3
space
arrow Table 4
space
arrow Table 5
space
arrow Table 6
space
arrow Table 7
space
arrow Table 8
space
arrow Table 9
space
arrow Table 10
space
arrow Table 11
space
arrow Table 12
space
arrow Table 13
space
arrow Table 14
space
arrow Table 15
space
arrow Table 16
space
arrow Table 17
space
arrow Table 18
space
arrow Table 19
space
arrow Table 20
space
arrow Table 21
space
arrow Technical Notes
space
 
LEGEND:
PDF Icon   Link to a PDF document
Non-CDC Web Link   Link to non-governmental site and does not necessarily represent the views of the CDC
Adobe Acrobat (TM) Reader needs to be installed on your computer in order to read documents in PDF format. Download the Reader.
spacer spacer
spacer
Skip Nav spacer
Contents
spacer
spacer
View PDF PDF icon
 
Cover
 
Commentary
 
Figure and Tables
   
Figure 1 Location of enhanced perinatal surveillance areas, 2000–2003
Table 1 Number and percentage of HIV-infected pregnant women who gave birth to a live infant, by year of infant’s birth and selected characteristics of mother, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 2 Prenatal care of HIV-infected women, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 3 Timing of HIV testing of HIV-infected women, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 4 Receipt of antiretroviral therapy by HIV-infected women and HIV-exposed infants, by timing of receipt and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 5 Method of delivery for HIV-infected women, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 6 Substance use and toxicology screening of HIV-infected women during pregnancy, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 7 Screening of HIV-infected women during pregnancy, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 8Number and percentage of HIV-infected women with positive test results for selected conditions, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 9 Prenatal care of HIV-infected women, by race/ethnicity and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 10 Timing of HIV testing of HIV-infected women, by race/ethnicity and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 11 Receipt of antiretroviral therapy by HIV-infected women and HIV exposed infants, by timing of receipt, race/ethnicity, and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 12 Method of delivery for HIV-infected women, by race/ethnicity and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 13 Substance use and toxicology screening of HIV-infected women during pregnancy, by race/ethnicity and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 14Type of birth, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 15 Number and percentage of infants receiving prophylaxis against Pneumocystis jiroveci pneumonia, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 16 Number and percentage of infants infected with HIV through mother-to-child transmission, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 17 Birth weight (grams) of children born to HIV-infected women, by race/ethnicity and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 18 Gestational age at birth among HIV-infected women, by race/ethnicity and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 19 Birth defects in first year of life in children born to HIV-infected women, by race/ethnicity and year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 20 Number and percentage of HIV-infected women who gave birth to a live infant and received medical treatment reimbursement, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
Table 21 Type of facility where prenatal care was provided, by year of infant’s birth, 2000–2003—24 areas conducting enhanced perinatal surveillance in the United States and dependent areas
 
Technical Notes
spacer
Last Modified: January 5, 2009
Last Reviewed: January 5, 2009
Content Source:
Divisions of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
spacer
spacer
spacer
Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
spacer
spacer
spacer Safer, Healthier People
spacer
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, 24 Hours/Every Day - cdcinfo@cdc.gov
spacer USA.gov: The U.S. Government's Official Web PortalDHHS Department of Health
and Human Services